Ulcerative Colitis

Can rectal vitamin E induce remission in patients with ulcerative colitis?

harminka — Sat, 01 Nov 2008 03:57:19 -0500

It is believed that the generation of an exaggerated intestinal immune response to otherwise innocuous stimuli along with generation of oxygen free radicals plays a key role in the pathophysiology of UC.

Ulcerative colitis accompany with strongyloides stercoralis infection

harminka — Wed, 24 Sep 2008 10:53:56 -0500

Although exacerbation of UC usually poses little diagnostic dilemma, physicians should remain cognizant to the possibility of an alternative cause for patient symptoms.

Long-term safety data on Lialda published in leading GI journal

harminka — Wed, 18 Jun 2008 11:50:48 -0500

Shire Limited, the global specialty biopharmaceutical company, announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda™ (mesalamine).

Alternative cure for Crohn's disease and ulcerative colitis

harminka — Tue, 17 Jun 2008 07:37:38 -0500

Two research studies evaluating dietary changes and complementary medicine for the treatment of inflammatory bowel diseases (IBD) have been launched at Rush University Medical Center.

New technique puts DNA profiling of E. coli on fast track

harminka — Tue, 11 Mar 2008 02:10:46 -0500

Using new genetic techniques, scientists are unlocking the secrets of how E coli bacteria contaminate food and make people sick.

Positive results from phase 1 clinical trials of cuprindro

harminka — Fri, 15 Feb 2008 13:31:13 -0600

Medical Therapies Limited today announced that it has completed its ‘first in human’ clinical trial of Cuprindo with interim results from patient diaries indicating that Cuprindo™ is safe and well tolerated.

Physician and patient perceptions regarding impact of UC

harminka — Fri, 07 Dec 2007 13:59:27 -0600

Nearly three out of four patients with ulcerative colitis (UC) consider feeling unwell to be a normal part of life, while gastroenterologists estimate this to be true for only 37 percent of their UC patients, according to results from a nationwide series of surveys presented today at the 2007 Crohn’s & Colitis Foundation’s 6th Annual Advances in the Inflammatory Bowel Diseases conference.

Asacol treats UC symptoms of isolated proctitis

harminka — Thu, 06 Dec 2007 05:25:52 -0600

Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an effective and well-tolerated treatment for patients with all extents of ulcerative colitis (UC), including isolated proctitis.

Colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients

harminka — Mon, 19 Nov 2007 07:24:46 -0600

A pilot study from researchers at Kyushu University in Fukuoka, Japan, found that narrow band imaging (NBI) colonoscopy used in cancer surveillance for ulcerative colitis patients can identify flat dysplastic lesions. The research appears in the November issue of Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy.

New therapeutic targets in the treatment of ulcerative colitis

harminka — Tue, 13 Nov 2007 14:04:38 -0600

Social, environmental and dietary changes are associated with the changes of disease spectrum in a country. Ulcerative colitis has become a commonly seen disease in China, probably due to extensive consumption of Western foods in recent years. Unfortunately, the etiology and pathogenesis of ulcerative colitis have not been clarified yet.

Eeffective strategy in Inflammatory Bowel Disease patients

harminka — Fri, 26 Oct 2007 08:01:44 -0500

Crohn's disease (CD) and ulcerative colitis (UC) are chronic-relapsing diseases, the clinical courses of which are characterized by periods of remission and periods of acute flare up, determining clinical symptoms which have a strong impact on the quality of life for patients.

Colectomy increases healthcare utilization, costs

harminka — Tue, 16 Oct 2007 09:16:00 -0500

Clinical data presented today at the annual meeting of the American College of Gastroenterology (ACG) show that REMICADE significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis (UC).